Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on Tc-Octreotide and posttherapeutic Lu-DOTA-TATE scans.

A 62-year-old woman with a history of abdominal pain presented with multiple hepatic lesions and dilatation of portal, splenic and superior mesenteric veins on the magnetic resonance imaging referred for a Tc-octreotide scan. Accordingly, similar octreotide-avid lesions were found as well as an uptake in the epigastric region conforming to the anatomy of the portocaval venous system, compatible with a tumor thrombosis. Then, the patient underwent two cycles of therapy with Lu-DOTA-TATE, on that the same appearance was observed.

"Picture-in-Picture" Artifact: Introduction and Characterization of a Hitherto Unrecognized Imaging Artifact in Creating Perfusion Defects in Myocardial Perfusion Single-Photon Emission Computed Tomography.

Following a moving hot spot in the projections of raw images and profound perfusion defects in myocardial perfusion single-photon emission computed tomography (SPECT) imaging of a patient, a hypothesis was postulated that the perfusion defects were artifactual, and the high activity concentration of the gallbladder may be a culprit for this phenomenon, owing to flawed event positioning function of the gamma camera due to a malfunctioning digital event processor electronics board. To depict the characteristics of this artifact, a point source containing an activity of 3 mCi of pertechnetate is placed on the scanning table with the detector facing the table (at a distance of 30 cm), and then, in other detector positions and 1-min static images are acquired accordingly. The ratio is calculated as follows: count of the artifactual focus: 1860, count of the index focus: 705,727, and artifactual-to-index focus ratio: 0.

Comparison of radioiodine ablation rates between low high dose, and according to the surgeon's expertise in the low-risk group of differentiated thyroid cancer.

Radioiodine ablation following surgery is the accepted treatment for patients with differentiated thyroid cancer (DTC). Since that surgical volume and radioiodine dose can have impact on treatment outcome, we aimed to evaluate them on the treatment outcome of low-risk DTC patients. Low-risk DTC patients were classified into four groups, including (1) thyroidectomy was performed by thyroid surgeon and low-dose (1850 MBq [30 mCi]) radioiodine was administered ( = 17), (2) thyroidectomy was performed by thyroid surgeon and high-dose (3700 MBq [100 mCi]) radioiodine was administered ( = 10), (3) thyroidectomy was performed by general surgeon and low-dose radioiodine was administered ( = 22), and (4) thyroidectomy was performed by general surgeon and high-dose radioiodine was administered ( = 29).